

Attention Business Editors:

Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis (A Common Type of Eczema)

BURNABY, BC, Dec. 11 /CNW/ - Welichem today announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study. The objectives of the trial are to evaluate the efficacy of the creams (0.5% and 1.0% WBI-1001) in comparison to the vehicle and also to evaluate the safety and tolerability of the creams in patients with atopic dermatitis.

The study is being conducted at three centers across Canada. It is planned that 150 patients will be enrolled in the trial that is anticipated to be concluded in 6 to 9 months.

The Company is also pleased to announce today that Dr. Michael Lyle, a long serving member and the former Director of CMC of the Company, was appointed as the Company's Vice President of Research and Development.

"Dr. Michael Lyle, is well qualified to lead the Company's research and development program. In addition to leading the Company's CMC program in the past few years, Dr Lyle has also successfully led two clinical trial applications related to the Company's lead drug candidate, WBI-1001, for the treatment of inflammatory skin diseases. He will be a very valuable asset for the Company's management team." said Dr. Liren Tang, the Company's CEO.

<<

ON BEHALF OF THE BOARD

Dr. Tan Xiangdong, Chairman of the Board

About Welichem Biotech Inc.

>>

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

%SEDAR: 00021386E

/For further information: Liren Tang, Chief Executive Officer. Tel.: (604) 432-1703, Email:lirentang(at)welichem.com/ (WBI.)

CO: Welichem Biotech Inc.

CNW 17:05e 11-DEC-09